Search Patents
-
Patent number: 5728553Abstract: A process for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, fragments of albumin, polymers or aggregates of albumin, and viruses, and which is relatively non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through two chromatography purifications, ultrafiltering the product, passing through two further chromatography steps and again ultrafiltering the product.Type: GrantFiled: May 25, 1995Date of Patent: March 17, 1998Assignee: Delta Biotechnology LimitedInventors: Andrew R. Goodey, Darrell Sleep, Hendrik van Urk, Stephen Berezenko, John R. Woodrow, Richard A. Johnson, Patricia C. Wood, Steven J. Burton, Alan V. Quirk, David St. J. Coghlan, Mark J. Wilson
-
Patent number: 5453490Abstract: A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.Type: GrantFiled: August 30, 1994Date of Patent: September 26, 1995Assignee: Synergen, Inc.Inventors: Robert Hageman, Stephen P. Eisenberg, David Dripps, Ronald Evans, Henryk Cudny, Robert C. Thompson
-
Patent number: 5179196Abstract: The present invention provides a process for the recovery of heterologous proteins from CTAP-III fusion proteins comprising expressing a fusion protein having a first amino acid sequence, a second amino acid sequence, and a selectable site which may be cleaved to provide first and second polypeptide fragments, respectively, wherein the first amino acid fragment is homologous to CTAP-III, and the first and second fragments have different pI values; cleaving the fusion protein to provide the first and second fragments; and separating the first and second fragments by ion exchange chromatography.Type: GrantFiled: May 4, 1989Date of Patent: January 12, 1993Assignee: SRI InternationalInventors: Paul H. Johnson, Ping Sze, Richard C. Winant, Jerome B. Lazar
-
Patent number: 4985544Abstract: Reactivation of cysteine-containing protein in a process, in which a reduced and denatured cysteine-containing protein such as salmon growth hormone I or eel growth hormone I can be efficiently reactivated.Type: GrantFiled: August 2, 1988Date of Patent: January 15, 1991Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yoshiharu Yokoo, Seiji Sugimoto
-
Patent number: 5099003Abstract: A method of preparing a sterile and stable plasma-protein solution containing fibrinogen and Factor XIII from human blood plasma which has been stabilized with citrate, comprising treating the plasma with .beta.-propiolactone and irradiating it with ultraviolet light, removing the Factors II, VII, IX and X by adsorption onto anion exchangers that adsorb proteins, precipitating the companion proteins out by adding ethanol until the solution has a final concentration of about 9% by volume at -3.degree. C., centrifuging the precipitate off, dissolving the precipitate in a citrate buffer at a pH of about 6.35 and a temperature of about 37.degree. C., adjusting the protein level of the solution to about 13.3 g/l with sodium citrate solution, adding ethanol, a glycine citrate buffer, and a solution of sodium citrate to precipitate out the companion proteins, adding ethanol to the remaining solution until the solution has a final concentration of about 9% by volume at -3.degree. C.Type: GrantFiled: October 12, 1988Date of Patent: March 24, 1992Assignee: Biotest Pharma GmbHInventors: Ronald Kotitschke, Axel W. Stemberger, Wolfgang Stephan
-
Patent number: 5116952Abstract: Substantially pure proteins active in humoral hypercalcemia of malignancy (PTHrP) and sub-units and fragments thereof. Antibody reagents capable of binding to epitopes of PTHrP. Methods and kits for the detection of PTHrP.Type: GrantFiled: May 9, 1988Date of Patent: May 26, 1992Assignee: The University of MelbourneInventors: Thomas J. Martin, Jane M. Moseley, Bruce E. Kemp, Richard E. H. Wettenhall
-
Patent number: 5525497Abstract: Purified nucleic acid encoding a yeast, human, or bovine poly(A) polymerase, where the bovine nucleic acid consists essentially of that nucleic acid sequence shown as nucleotide SEQ. ID. NO.: 1; the resulting recombinant poly(A) polymerase expressed from these nucleic acids, corresponding methods of their production, and methods of use of the poly(A) polymerase.Type: GrantFiled: November 27, 1991Date of Patent: June 11, 1996Inventors: Walter Keller, Joachim Lingner, Georges Martin, Elmar Wahle
-
Patent number: 5264549Abstract: A purified protein, factor J, which has inhibitory properties which prevent the formation or the dissociation of Cl complex and a method of purification for said protein. The method including the following sequential chromatography steps: anion exchange, QAE-"SEPHADEX", heparin-"SEPHAROSE" affinity, "MONO Q" and hydroxylapatite.Type: GrantFiled: April 27, 1992Date of Patent: November 23, 1993Assignee: The Beth Israel Hospital AssociationInventor: Anne Nicholson-Weller
-
Patent number: 5268363Abstract: A purified protein, factor J, which has inhibitory properties which prevent the formation or the dissociation of Cl complex and a method of purification for said protein. The method including the following sequential chromatography steps: anion exchange QAE-"SEPHADEX", heparin-"SEPHAROSE" affinity, "MONO Q" and hydroxylapatite.Type: GrantFiled: April 27, 1992Date of Patent: December 7, 1993Assignee: The Beth Israel Hospital AssociationInventor: Anne Nicholson-Weller
-
Patent number: 5008377Abstract: A method for the preparation of a protein in a physiologically active or native form, which method includesproviding a source of protein in a solubilized form,and a cationic exchange medium;contacting the source of protein and cationic exchange medium; andrecovering the protein in a physiologically active form.Type: GrantFiled: April 21, 1988Date of Patent: April 16, 1991Assignee: Bunge (Australia) Pty. Ltd.Inventors: Joseph J. Patroni, Malcolm R. Brandon
-
Patent number: 5077390Abstract: A substantially pure, hemagglutinin-free composition of trichosanthin, and a method of producing the composition is disclosed. A plant extract from Trichosanthes kirilowii is contacted with an anionic exchange resin to remove contaminating hemagglutinins, and trichosanthin is further purified from the extract by cation exchange chromatography to a purity of greater than 95%.Type: GrantFiled: September 7, 1989Date of Patent: December 31, 1991Assignee: Genelabs, IncorporatedInventors: Paul S. Wu, Susan B. Wade, Raul R. Soikes
-
Patent number: 4983722Abstract: Protein A is selectively isolated from an antibody--Protein A mixture by exposing the mixture to an anion exchange material under conditions sufficient to adsorb both components and then sequentially eluting the antibodies and protein A under conditions of increasing ionic strength. Resulting antibody preparations have less than about 15 ng of Protein A per mg of antibody.Type: GrantFiled: June 8, 1988Date of Patent: January 8, 1991Assignee: Miles Inc.Inventors: James W. Bloom, Melvin F. Wong, Gautam Mitra
-
Patent number: 4981952Abstract: The recovery of vitamin K-dependent proteins produced by transformed microorganisms can be effected from the cell culture medium utilizing the changes in the protein which occur in the presence of divalent cations. The present process uses divalent cations to alter the binding affinity of the proteins and thereby selectively elute the proteins away from contaminants in the culture medium using standard chromatography.Type: GrantFiled: August 16, 1989Date of Patent: January 1, 1991Assignee: Eli Lilly and CompanyInventor: S. Betty Yan
-
Patent number: 5270449Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.Type: GrantFiled: September 14, 1992Date of Patent: December 14, 1993Assignee: American Cyanamid CompanyInventors: Peter Bohlen, Peter Gautschi-Sova
-
Patent number: 4992531Abstract: A method for the recovery of proteins in a solubilized form from host cells including providing a source of host cells incorporating a synthesized or expressed protein; providing a source of at least one cationic surfactant; and treating the host cells with at least one cationic surfactant, in an amount sufficient to effect solubilization of the proteins.Type: GrantFiled: June 13, 1988Date of Patent: February 12, 1991Assignee: Bunge (Australia) Pty. Ltd.Inventors: Joseph J. Patroni, Malcolm R. Brandon
-
Patent number: 5415859Abstract: The protein doublet H110D, the individual components thereof, and the production and use thereof in a vaccine against a nematode infection. This protein doublet is a plasma membrane-associated protein material of the intestinal microvilli of Haemonchus contortus. H110D has a molecular weight of about 110 kd and reacts with antibodies raised in animals injected with a contortin-enriched fraction. Injection of preparations of the protein doublet H110D or its components induces the production of specific protective antibodies.Type: GrantFiled: August 14, 1992Date of Patent: May 16, 1995Inventor: Edward A. Munn
-
Patent number: 5314993Abstract: The invention concerns a process for purifying protein A preparations to high purity with high product yield. Where the protein A is obtained from a Gram-negative recombinant microbe hosting a vehicle containing a gene encoding protein A, the protein A is purified to high purity, and, advantageously, to very low levels of endotoxin. The protein A preparations made via the invention process are useful in therapeutic application, e.g., therapeutic plasma exchange, as well as for other well-known uses of protein A.Type: GrantFiled: February 10, 1992Date of Patent: May 24, 1994Assignee: Repligen CorporationInventors: Richard N. Love, Albert T. Profy
-
Patent number: 5075423Abstract: Affinity-purified protein A preparations are contacted with a suitable anionic exchange material in order to remove trace contamination. Staphylococcal enterotoxin B (SEB) and other proteinaceous contaminants are removed by passing such affinity-purified protein A preparations through a DEAE-cellulose column and thereafter selectively eluting the protein A to separate the contaminants. Very high purity protein A composition are thus obtained, typically having a contaminant concentration of about 5 weight % or below, with below about 0.001 weight % SEB.Type: GrantFiled: January 24, 1990Date of Patent: December 24, 1991Assignee: Imre CorporationInventor: Joseph P. Balint, Jr.
-
Patent number: 5101014Abstract: The present invention comprises a method for the purification of the 69 kDa outer membrane protein of Bordetella B. pertussis and the protein purified therewith. A preferred embodiment comprises the purification of the 69 kDa protein from Bordetella B. pertussis strain Bp 353. The present process is advantageous in that it does not require or involve the use of biologics (such as monoclonal antibodies) and therefore simplifies the purification procedure and makes the resulting purified protein particularly advantageous for inclusion in acellular vaccines.Type: GrantFiled: February 10, 1989Date of Patent: March 31, 1992Assignee: United States of AmericaInventors: Drusilla L. Burns, Michael J. Brennan, Jeanine L. Gould-Kostka, Charles R. Manclark
-
Patent number: 5169936Abstract: A process for the purification of proteins from solutions containing contaminants of similar net charge and molecular weight is provided, comprising contacting a solution containing the desired protein with an immobilized metal affinity chromatography resin in a buffer containing a low concentration of a weak ligand for the chelant of the resin. The adsorbed protein is then eluted using a buffer having a high concentration of the same weak ligand, e.g., Tris. Particularly preferred features employ agarose-iminodiacetic acid resins having copper cations and are especially useful in obtaining preparations of homogeneous, stable rsT4 proteins.Type: GrantFiled: April 14, 1989Date of Patent: December 8, 1992Assignee: Biogen, Inc.Inventors: Mark A. Staples, Christopher A. Pargellis